Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Cirius Therapeutics Inc. has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. Prosecution activity is distributed across a single distinct examiner and a sole distinct art unit, reflecting a singular point of contact for the company's current patent applications. Such a focused arrangement often occurs when a company is pursuing a specific therapeutic candidate or a single core technology within the pharmaceutical space. This allows the applicant to develop a deep understanding of the examiner's specific concerns regarding patentability in this technical field.
The busiest examiner, SHIM, DAVID M., is responsible for 1 busiest examiner pending office action. Since there is only a single pending office action in total, this examiner manages the entire active portfolio, requiring a focused strategy for this specific pharmaceutical matter. Practitioners should note that the prosecution outcome for the company's current filings depends entirely on the interactions with this individual examiner. Maintaining a clear and consistent dialogue with this sole official is critical for the advancement of the company's intellectual property goals.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SHIM, DAVID M. | 1 | 59.2% | +57.2% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18435285 | THIAZOLIDINEDIONE ANALOGS FOR THE TREATMENT OF NAFLD AND METABOLIC DISEASES | SHIM, DAVID M. | — |
| Art Unit | Apps |
|---|---|
| 1626 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18435285 | THIAZOLIDINEDIONE ANALOGS FOR THE TREATMENT OF NAFLD AND METABOLIC DISEASES | SHIM, DAVID M. | 1626 | §103§112DP | Non-Final OA | — | Pending | Feb 07, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCirius Therapeutics Inc. has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
David M. Shim has the most, with 1 of Cirius Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.